Abcam, ab250467, Anti-FXYD6/Plp antibody [EPR9004(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal FXYD6/Plp antibody. Carrier free. Suitable for IP, WB and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR9004(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab250467 is the carrier-free version of
ab181254
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FXYD6 also known as phospholemman-like protein (Plp) is a member of the FXYD family that regulates ion transport. This protein has a mass of around 9 kDa and demonstrates specificity in modulating sodium-potassium (Na+/K+) ATPase activity. The expression of FXYD6 is quite widespread but appears higher in tissues such as brain and kidney suggesting its important roles in these organs' physiological functions. It influences ion balance and potentially affects cellular excitability and fluid transport through its modulation of ion channels and pumps.
Biological function summary
FXYD6 impacts multiple cellular mechanisms mainly through its association with Na+/K+ ATPase complex. It influences ion gradients across the plasma membrane an essential factor in maintaining cell volume and resting membrane potential. Interactions within this complex suggest FXYD6 plays an important part in fine-tuning ion pump efficiency affecting the overall cellular ionic homeostasis. Its precise role within the ATPase complex is important for adapting the function of these pumps to specific physiological conditions.
Pathways
FXYD6 integrates into ion transport and signal transduction pathways particularly those involving Na+/K+ ATPase. It cooperates with other FXYD proteins like FXYD2 in adjusting ion pump functionality ensuring cells respond adequately to physiological stimuli. FXYD6 modulates the ATPase in neural and renal tissues linking it to neural signaling pathways such as neurotransmission processes and kidney regulation pathways.
FXYD6 has associations with schizophrenia and renal diseases. In schizophrenia alterations in FXYD6 expression or function can affect neural ion balance potentially contributing to the disorder's pathophysiology. In renal diseases aberrant FXYD6 activity can disrupt kidney ion transport implicating it in conditions like hypertension. Through these disorders FXYD6 connects with proteins such as FXYD2 and gamma subunits of Na+/K+ ATPase impacting the pathological outcomes.